SCHEMBL2775700

SCHEMBL2775700

CC(=O)ON(C=O)c1ccc(F)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.35
APP P05067 3/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
NPC1 O15118 2/20 0.35
TP53 P04637 2/20 0.35
RAB9A P51151 2/20 0.35
MMP13 P45452 2/20 0.35
MMP14 P50281 2/20 0.35
CYP3A4 P08684 1/20 0.35
ADAMTS4 O75173 1/20 0.35
ALDH1A1 P00352 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
SNCA P37840 1/20 0.34
BRCA1 P38398 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28531019 0.69 NFE2L2 (0.44) LMNACYP1A2SMN1; SMN2NPC1TP53
SCHEMBL4633234 0.66 TSHR (0.56) APPCYP1A2CYP2C19MEN1MAPT
SCHEMBL2096896 0.66 APP (0.48) APPCYP1A2CYP2C19SMN1; SMN2NPC1
Acetone SCHEMBL27946364 0.66 CES2 (0.58) NPC1RAB9AALDH1A1MEN1MAPT
SCHEMBL9185766 0.65 APP (0.41) LMNAAPPCYP1A2CYP2C19SMN1; SMN2
SCHEMBL17671283 0.65 TSHR (0.42) APPCYP1A2CYP2C19MEN1KMT2A
SCHEMBL6393684 0.65 SMN1; SMN2 (0.56) LMNAAPPSMN1; SMN2NPC1TP53
SCHEMBL27662343 0.65 TSHR (0.42) APPCYP1A2CYP2C19ALDH1A1MEN1
Acetic Acid SCHEMBL27477631 0.63 CES2 (0.55) NPC1RAB9AALDH1A1MEN1KMT2A
SCHEMBL11257841 0.63 TSHR (0.41) APPCYP1A2CYP2C19MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2435433-B1 (DIHYDRO)IMIDAZOISO[5,1-A]QUINOLINES AS FSH RECEPTOR AGONISTS FOR THE TREATMENT OF FERTILITY DISORDERS MERCK SHARP & DOHME (NL) 2013-08-28 EP disclosed
US-8071587-B2 (Dihydro)imidazoiso[5,1-A]quinolines N. V. ORGANON (NL) 2011-12-06 US disclosed
US-20100324021-A1 (DIHYDRO)IMIDAZOISO[5,1-A]QUINOLINES N.V. ORGANON (NL) 2010-12-23 US disclosed
WO-2010136438-A1 (DIHYDRO) IMIDAZOISO (5, 1-A) QUINOLINES AS FSH RECEPTOR AGONISTS FOR THE TREATMENT OF FERTILITY DISORDERS N.V. ORGANON (NL) 2010-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324021-A1 (DIHYDRO)IMIDAZOISO[5,1-A]QUINOLINES NQO2, IPO5, SCN5A LMNA 3298/4885APP 4840/4885CYP1A2 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.